Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China

Core Viewpoint - Idorsia Ltd. announces the launch of QUVIVIQ (daridorexant) in China by Simcere Pharmaceuticals, marking a significant advancement in insomnia treatment without the limitations of traditional psychotropic medications [1][4][5]. Group 1: Product Launch and Clinical Profile - QUVIVIQ is a dual orexin receptor antagonist indicated for adult patients with insomnia, specifically targeting difficulties in falling and maintaining sleep [1]. - The drug has been approved without psychotropic drug control labeling, highlighting its unique clinical profile compared to existing treatments [1][5]. - Daridorexant selectively blocks orexin neuropeptides, regulating wake signaling and promoting restorative sleep, with approximately 80% elimination within the first 8 hours of dosing [3]. Group 2: Market Need and Impact - Insomnia poses a significant public health challenge in China, with current treatments often leading to next-day drowsiness and dependence, creating a substantial unmet need for safer alternatives [2]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and total sleep time, with notable enhancements in daytime functioning as measured by the IDSIQ [5]. Group 3: Collaboration and Financial Aspects - Idorsia and Simcere entered an exclusive licensing agreement for QUVIVIQ in Greater China, with Idorsia receiving $80 million in milestone payments and potential future royalties [6]. - The collaboration aims to ensure rapid access to QUVIVIQ for patients in need, positioning it as a meaningful advancement in chronic insomnia treatment [5]. Group 4: Availability and Global Reach - Daridorexant is commercially available as QUVIVIQ in multiple countries, including the US, Germany, and now China, and is approved throughout the EU [7].